🔎Long-term malignancy risk remains an important consideration in RA treatment See the SELECT trial program 5-year malignancy risk data for a JAKi and TNFi in RA, including in high CV-risk patients: https://t.co/zAqwTsKJ3S Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/6tIplvqAWg

Dr. Lisa Stamp highlights crucial pharmacologic implications of COL use for gout flares in pts w/ comorbidities: - Dose adjustment in CKD - Be mindful of potential drug interactions @RheumNow #APLAR2026 https://t.co/efA7ptFF7Y

AxSpA SIG : Baraliakos - inflammation drives fatty lesions producing damage and osteoblastic activity @RheumNow @APLAR2026 https://t.co/GDFSwt2IOm

Why phenotype OA? Mechanisms, course and treatment response vary. Three knees at the same Kellgren-Lawrence grade 2 can differ: post-meniscal varus pain, obesity with synovitis, or widespread tenderness etc. X-ray grade alone misses this. OA:SIG #APLAR26 @RheumNow https://t.co/RWtq3ORGwc

Mease : future therapy - Be-Bold H2H Bime vs Rizi, Sonelokimab, Izokibep, Deucra, Zaso, Ico, TL1Ainhib @RheumNow #APLAR2026 https://t.co/Rv5hwnQnDl

Prof. AHoi presented their study on ESR as potential source of risk info in SLE 48% discordance bet ESR & conv. serology Isolated ⬆️ESR levels showed ⬆️ assoc with dse activity and flare; risk increases further if combi ⬆️ESR+low c3/4+antidsDNA @RheumNow #APLAR2026 https://t.co/BvC0OZFjd5

Menopause Hormone Therapy Tied to Small Autoimmune Disease Risk Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested. https://t.co/kV4Y7tvpC8

Rituximab or Azathioprine for EGPA Maintenance? A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone. https://t.co/UrHqPBVibn https://t.co/cpusNcpYWd

Grappa Symposium: Leung Obesity in PsA - done deal @RheumNow #APLAR2026 https://t.co/3YQT4kiPer

AxSpA+rash vs Axial PsA Kishimoto : two phenotypes of the same disease and to maximise specificity Axis study - imaging criteria = AxSpA phenotype @RheumNow #APLAR2026 https://t.co/UYFnA3AyUM

An important and relevant reminder from @rheumarhyme on AI use @RheumNow #APLAR2026 https://t.co/7Ratb6aQOD

AI can be helpful in manuscript creation As the author: > always verify the draft - allow time to check > take full responsibility of the content - review and revise the final manuscript @RheumNow #APLAR2026 https://t.co/cQsEtDc7z1

Case quiz: 38F fever, tetraparesis, hallucinations, slurred speech. Low C3, ANA 1:100, WBC 26,320, normal CSF/Ca/PTH. CT: basal ganglia calcification. Dx? Answer: SLE with Fahr syndrome (focal NPSLE) plus urosepsis. Keep infection in rheum Ddx. P#325 #APLAR26 @RheumNow https://t.co/Gsb8dquwHL

Dr. Poddubny on AI & machine learning in SpA AI has enabled the analysis of large data sets offering a support for clinical decision-making. Future directions? Making scans faster leading to rapid analysis Challenge: access to large, high quality data @RheumNow #APLAR2026 https://t.co/UhdjSRXtOv

Better drugs only help if patients can get them. In an APLAR PsA registry, 43% of lowest-GDP patients had not reached MDA and were not on a biologic or targeted DMARD. Coverage, reimbursement and social support needed, not just science. P#242 #APLAR26 @RheumNow https://t.co/Rms4QsbcII